D M Pharma (Mkt.) Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 23-10-2024
- Paid Up Capital ₹ 5.00 Cr
as on 23-10-2024
- Company Age 12 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.19 Cr
as on 23-10-2024
- Revenue -17.73%
(FY 2023)
- Profit -31.25%
(FY 2023)
- Ebitda -23.48%
(FY 2023)
- Net Worth 8.19%
(FY 2023)
- Total Assets -22.35%
(FY 2023)
About D M Pharma (Mkt.)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 5.00 Cr.
The company currently has active open charges totaling ₹4.19 Cr.
Dinesh Aggarwal and Gautam serve as directors at the Company.
- CIN/LLPIN
U24232CH2012PTC033864
- Company No.
033864
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jun 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does D M Pharma (Mkt.) Private Limited offer?
D M Pharma (Mkt.) Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Fitness Supplements, Common Disease Medicines, Nasal Drops, Psoriasis Ointment, Digestive System Drugs & Medicines, Antacid Drugs, Anti Infective Drugs & Medicines, Antibacterial Drugs, Nutritional Supplements.
Who are the key members and board of directors at D M Pharma (Mkt.)?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dinesh Aggarwal  | Director | 16-Aug-2018 | Current |
| Gautam | Whole-Time Director | 01-Apr-2023 | Current |
Financial Performance and Corporate Structure Insights of D M Pharma (Mkt.).
D M Pharma (Mkt.) Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 17.73% decrease. The company also saw a substantial fall in profitability, with a 31.25% decrease in profit. The company's net worth moved up by a moderate rise of 8.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of D M Pharma (Mkt.)?
In 2023, D M Pharma (Mkt.) had a promoter holding of 75.00% and a public holding of 25.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 30 Jul 2022 | ₹2.06 M | Open |
Hdfc Bank Limited Creation Date: 20 Jun 2022 | ₹2.64 M | Open |
Hdfc Bank Limited Creation Date: 17 May 2021 | ₹1.82 Cr | Open |
How Many Employees Work at D M Pharma (Mkt.)?
D M Pharma (Mkt.) has a workforce of 12 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of D M Pharma (Mkt.), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped D M Pharma (Mkt.)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
